VERAXA Biotech (NASDAQ: VRXA) has announced a collaboration with Ardigen S.A., an AI-driven bioinformatics company, to support the development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates. The partnership will initially focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA’s BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity.
VERAXA said integrating artificial intelligence into its research and development strategy could enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity. The company believes the collaboration will strengthen development of precision oncology therapies and improve long-term drug development success rates. The full press release is available at https://ibn.fm/GLFg2.
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
The collaboration with Ardigen represents a strategic move to leverage artificial intelligence in drug discovery, a trend that is gaining momentum across the pharmaceutical industry. By applying AI to analyze complex biological data, VERAXA aims to identify more effective and safer drug candidates. This approach could potentially accelerate the development of therapies for cancers that are difficult to treat with conventional methods.
Investors and stakeholders can find the latest news and updates relating to VRXA in the company’s newsroom at https://ibn.fm/VRXA. Forward-looking statements in this article involve risks and uncertainties, and actual results may differ materially. These risks are detailed in the company's SEC filings. The original release can be viewed at https://www.newmediawire.com.
